<DOC>
	<DOCNO>NCT01133561</DOCNO>
	<brief_summary>The study ass effectiveness Pioglitazone cellular clinical level term improvement skin systemic manifestation psoriasis . The investigator assume pioglitazone ( one thiazolidinediones readily available Egypt ) , regulate keratinocytes ' disorder proliferation observe psoriasis , addition improve insulin resistance peripheral tissue observe many psoriatic patient cause metabolic syndrome . This allow give safer therapy available one psoriasis treat patient global perspective .</brief_summary>
	<brief_title>Pioglitazone Psoriasis- A Clinical Molecular Study .</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Age ≥ 18 year less 65 year . Plaque psoriasis vulgaris ≥ 10 % ( apart palmoplantar psoriasis include ) . Age le 18 year 65 year Mild psoriasis le 10 % body surface area Erythrodermic pustular psoriasis Liver disease , cardiac disease ( suspected history ECG ) , major medical disorder detect history . Pregnant lactating female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>metabolic syndrome</keyword>
	<keyword>pioglitazone</keyword>
	<keyword>randomize control trial</keyword>
</DOC>